Neurocrine Biosciences
NBIX
#1661
Rank
S$16.82 B
Marketcap
S$167.24
Share price
-1.25%
Change (1 day)
27.28%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): S$0.81 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are S$2.86 Billion. , an increase over its 2024 earnings that were of S$0.77 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 S$0.80 B3.9%
2024 S$0.77 B96.41%
2023 S$0.39 B41.13%
2022 S$0.28 B73.74%
2021 S$0.16 B-8.82%
2020 S$0.17 B77.78%
2019 S$99.72 M49.83%
2018 S$66.55 M-142.57%
2017 -S$0.16 Billion-14.73%
2016 -S$0.19 Billion53.15%
2015 -S$0.12 Billion46.25%
2014 -S$81.86 Million29.66%
2013 -S$63.14 Million-3530.8%
2012 S$1.84 M-95.73%
2011 S$43.11 M
2009 -S$60.61 Million-45.38%
2008 -S$0.12 Billion-58.87%
2007 -S$0.27 Billion87.3%
2006 -S$0.15 Billion351.97%
2005 -S$31.87 Million-52.09%
2004 -S$66.52 Million-10.98%
2003 -S$74.72 Million
2001 -S$55.77 Million
1999 -S$25.16 Million108.32%
1998 -S$12.08 Million
1996 S$3.68 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
S$12.95 B 1,501.26%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$8.38 B 936.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$32.70 B 3,942.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$0.10 B-86.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-S$53.08 Million-106.56%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$64.24 M-92.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-S$6.1 Million-100.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.07 B 156.38%๐Ÿ‡ฌ๐Ÿ‡ง UK